** Shares of gene sequencing equipment maker Illumina ILMN.O fall 4.7% to $117 premarket
** Co, late on Thursday, forecast 2025 revenue largely below Wall Street estimates
** Co expects 2025 revenue between $4.28 bln and $4.40 bln, below analysts' average estimate of $4.39 bln at midpoint, according to data compiled by LSEG
** China, which accounts for about 7% of Illumina's sales, placed co on its "unreliable entity" list earlier this week
** Illumina said its forecast does not reflect any impact from announcement from China
** "The lack of adjusting could mean there's hope they could be removed from the 'unreliable entity list' or that they can't yet quantify it" - Piper Sandler analysts
** Up to last close, stock down ~12% in the past 12 months
(Reporting by Mariam Sunny in Bengaluru)
((Mariam.ESunny@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。